56.69
56.69 (0%)
As of Feb 14, 2025
Rhythm Pharmaceuticals, Inc. [RYTM]
Source:
Company Overview
Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing our melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by MC4R pathway diseases.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | (857) 264-4280 |
| Industry | manufacturing |
| CEO | David P. Meeker M.D. |
| Website | www.rhythmtx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $130.1 |
| Operating Profit | $-265.5 |
| Net Income | $-260.6 |
| Net Cash | $29.2 |
Profit Ratios
| Gross Margin | $116.8 |
| Operating Margin | -204 |
| Profit as % of Revenues | -44.8% |
| Profit as % of Assets | -71.9% |
| Profit as % of Stockholder Equity | -1,199.3% |
Management Effectiveness
| Return on Equity | -1,199.3% |
| Return on Assets | -66.4% |
| Turnover Ratio | 35.9% |
| EBITA | $-265.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $392.3 |
| Total Liabilities | $227.7 |
| Operating Cash Flow | $-113.9 |
| Investing Cash Flow | $-48.2 |
| Financing Cash Flow | $191.2 |
